Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom.
The Healthcare Improvement Studies Institute, University of Cambridge, Cambridge, United Kingdom.
JAMA. 2020 May 26;323(20):2039-2051. doi: 10.1001/jama.2020.4871.
Deprescribing of antihypertensive medications is recommended for some older patients with polypharmacy and multimorbidity when the benefits of continued treatment may not outweigh the harms.
This study aimed to establish whether antihypertensive medication reduction is possible without significant changes in systolic blood pressure control or adverse events during 12-week follow-up.
DESIGN, SETTING, AND PARTICIPANTS: The Optimising Treatment for Mild Systolic Hypertension in the Elderly (OPTIMISE) study was a randomized, unblinded, noninferiority trial conducted in 69 primary care sites in England. Participants, whose primary care physician considered them appropriate for medication reduction, were aged 80 years and older, had systolic blood pressure lower than 150 mm Hg, and were receiving at least 2 antihypertensive medications were included. Participants enrolled between April 2017 and September 2018 and underwent follow-up until January 2019.
Participants were randomized (1:1 ratio) to a strategy of antihypertensive medication reduction (removal of 1 drug [intervention], n = 282) or usual care (control, n = 287), in which no medication changes were mandated.
The primary outcome was systolic blood pressure lower than 150 mm Hg at 12-week follow-up. The prespecified noninferiority margin was a relative risk (RR) of 0.90. Secondary outcomes included the proportion of participants maintaining medication reduction and differences in blood pressure, frailty, quality of life, adverse effects, and serious adverse events.
Among 569 patients randomized (mean age, 84.8 years; 276 [48.5%] women; median of 2 antihypertensive medications prescribed at baseline), 534 (93.8%) completed the trial. Overall, 229 (86.4%) patients in the intervention group and 236 (87.7%) patients in the control group had a systolic blood pressure lower than 150 mm Hg at 12 weeks (adjusted RR, 0.98 [97.5% 1-sided CI, 0.92 to ∞]). Of 7 prespecified secondary end points, 5 showed no significant difference. Medication reduction was sustained in 187 (66.3%) participants at 12 weeks. Mean change in systolic blood pressure was 3.4 mm Hg (95% CI, 1.1 to 5.8 mm Hg) higher in the intervention group compared with the control group. Twelve (4.3%) participants in the intervention group and 7 (2.4%) in the control group reported at least 1 serious adverse event (adjusted RR, 1.72 [95% CI, 0.7 to 4.3]).
Among older patients treated with multiple antihypertensive medications, a strategy of medication reduction, compared with usual care, was noninferior with regard to systolic blood pressure control at 12 weeks. The findings suggest antihypertensive medication reduction in some older patients with hypertension is not associated with substantial change in blood pressure control, although further research is needed to understand long-term clinical outcomes.
EudraCT Identifier: 2016-004236-38; ISRCTN identifier: 97503221.
对于一些患有多种疾病且同时服用多种药物的老年患者,当继续治疗的益处可能不如危害大时,建议减少降压药物的使用。
本研究旨在确定在 12 周的随访期间,降压药物的减少是否可以在不显著改变收缩压控制或不良事件的情况下实现。
设计、地点和参与者:优化治疗轻度老年收缩期高血压(OPTIMISE)研究是一项在英格兰 69 个基层医疗场所进行的随机、非盲、非劣效性试验。参与者的初级保健医生认为他们适合减少药物治疗,年龄在 80 岁及以上,收缩压低于 150mmHg,并且正在服用至少 2 种降压药物。参与者于 2017 年 4 月至 2018 年 9 月期间入组,并在 2019 年 1 月前进行随访。
参与者被随机(1:1 比例)分为降压药物减少策略组(减少 1 种药物[干预组],n=282)或常规护理组(对照组,n=287),对照组没有强制进行药物调整。
主要结局是 12 周随访时收缩压低于 150mmHg。预设的非劣效性边界为相对风险(RR)0.90。次要结局包括维持药物减少的参与者比例,以及血压、虚弱、生活质量、不良影响和严重不良事件的差异。
在 569 名随机分组的患者(平均年龄 84.8 岁;276 [48.5%]名女性;基线时平均服用 2 种降压药物)中,有 534 名(93.8%)完成了试验。总体而言,干预组 229 名(86.4%)患者和对照组 236 名(87.7%)患者在 12 周时收缩压低于 150mmHg(调整后的 RR,0.98 [97.5% 1 侧置信区间,0.92 至 ∞])。在 7 个预设的次要终点中,有 5 个没有显著差异。在 12 周时,187 名(66.3%)参与者维持了药物减少。与对照组相比,干预组的收缩压平均变化为 3.4mmHg(95%CI,1.1 至 5.8mmHg)。干预组有 12 名(4.3%)患者和对照组有 7 名(2.4%)患者报告了至少 1 例严重不良事件(调整后的 RR,1.72 [95%CI,0.7 至 4.3])。
在接受多种降压药物治疗的老年患者中,与常规护理相比,药物减少策略在 12 周时的收缩压控制方面不劣于常规护理。研究结果表明,在一些患有高血压的老年患者中,减少降压药物的使用并不会显著改变血压控制水平,但需要进一步研究以了解长期临床结局。
EudraCT 标识符:2016-004236-38;ISRCTN 标识符:97503221。